OverviewSuggest Edit

DAXOR is a biotechnology company that provides original medical equipment for medical personnel. The Company manufactures the BVA-100 Blood Volume Analyzer, the first machine approved by the FDA that provides rapid direct measurement of a patient’s blood volume. 

TypePublic
Founded1970
HQNew York, NY, US
Websitedaxor.com

Latest Updates

Employees (est.) (Jun 2017)37
Revenue (FY, 2011)$1.4 M
Share Price (Mar 2021)$11.4
Cybersecurity ratingBMore

Key People/Management at DAXOR

Michael R. Feldschuh

Michael R. Feldschuh

Director
Michael Feldschuh

Michael Feldschuh

President and Chief Executive
Jonathan Feldschuh

Jonathan Feldschuh

Chief Scientific Officer
James A. Lombard

James A. Lombard

Director
Peter Fetzer

Peter Fetzer

Corporate Counsel
Robert J. Michel

Robert J. Michel

CFO
Show more

DAXOR Office Locations

DAXOR has an office in New York
New York, NY, US (HQ)
350 5th Ave #4740
Show all (1)

DAXOR Financials and Metrics

DAXOR Revenue

DAXOR's revenue was reported to be $1.45 m in FY, 2011
USD

Revenue (FY, 2011)

1.4m

Gross profit (FY, 2011)

793.8k

Gross profit margin (FY, 2011), %

54.9%

Net income (FY, 2011)

(7.2m)

EBIT (FY, 2011)

(5.8m)

Market capitalization (5-Mar-2021)

46.0m

Closing stock price (5-Mar-2021)

11.4

Cash (31-Dec-2011)

59.6k

EV

46.0m
DAXOR's current market capitalization is $46 m.
Annual
USDFY, 2011

Revenue

1.4m

Cost of goods sold

652.5k

Gross profit

793.8k

Gross profit Margin, %

55%
Quarterly
USDQ2, 2011Q3, 2011

Revenue

358.1k340.9k

Cost of goods sold

160.7k149.4k

Gross profit

197.4k191.5k

Gross profit Margin, %

55%56%
Annual
USDFY, 2011

Cash

59.6k

Accounts Receivable

219.7k

Prepaid Expenses

209.3k

Inventories

301.5k
Quarterly
USDQ2, 2011Q3, 2011

Cash

111.8k29.7k

Accounts Receivable

193.5k189.6k

Prepaid Expenses

184.3k338.3k

Inventories

357.3k313.5k
Annual
USDFY, 2011

Net Income

(7.2m)

Depreciation and Amortization

290.8k

Inventories

(62.1k)

Accounts Payable

88.6k
Quarterly
USDQ2, 2011Q3, 2011

Net Income

(1.5m)(5.7m)

Depreciation and Amortization

147.0k219.5k

Inventories

(6.3k)(50.1k)

Accounts Payable

626.1k534.6k
USDQ2, 2011

Financial Leverage

2.1 x
Show all financial metrics

DAXOR Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

DAXOR Online and Social Media Presence

Embed Graph

DAXOR News and Updates

Daxor to Present at the H.C. Wainwright Global Life Sciences Conference

NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will present at the H.C. Wainwright Global Life Sciences Conference which is being held from March 9th to 1…

Daxor Corporation Announces $0.48 Per Share NAV Increase and Files Annual Report for Fiscal 2020

Revenues of Operating Division Increase by 50.4%

DAXOR CORPORATION AWARDED GRANT FROM THE CENTER FOR ADVANCING POINT OF CARE TECHNOLOGIES (CAPCAT) TO DEVELOP A POINT-OF-CARE BLOOD VOLUME ANALYZER

NEW YORK, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, announces today that it has been awarded a grant from the Center for Advancing Point of Care Technologies (CAPCaT), a program run by the Massachusetts Medical De…

Daxor to Present at the Inaugural H.C. Wainwright BioConnect 2021 Conference

NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology (organized as an investment company with fully-owned innovative medical instrumentation and biotechnology operations), today announces that Michael Feldschuh, Dax…

Daxor Corporation Announces Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout the U.S.

NEW YORK, NY, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces additional acquisitions of Daxor’s BVA-100® Blood Volume Analyzer at ma…
Show more

DAXOR Blogs

Daxor Corporation Receives ISO 13485 Quality Management System Certification for the Blood Volume Analyzer (BVA-100®)

Important Milestone for International Distribution NEW YORK, FEBRUARY 19, 2021– Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, announces today that it has been officially recognized as meeting all the requirements of ISO 13485; Medical Devices, Quality M…

Daxor Corporation Awarded Grant from the Center for Advancing Point of Care Technologies (Capcat) to Develop a Point-Of-Care Blood Volume Analyzer

NEW YORK, FEBRUARY 5, 2021– Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, announces today that it has been awarded a grant from the Center for Advancing Point of Care Technologies (CAPCaT), a program run by the Massachusetts Medical Device Development C…

Daxor Corporation to Exhibit at The Society for Critical Care Medicine 50Th Congress Virtual Event

NEW DATA SCHEDULED FOR PRESENTATION ON DAXOR’S BVA-100® BLOOD TEST  NEW YORK, JANUARY 26, 2021– Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology (organized as an investment company with fully owned innovative medical instrumentation and biotechnology operat…

Daxor Announces New Distribution Agreement with L1 Enterprises Government Distributor

NEW YORK, JANUARY 13, 2021– Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology (organized as an investment company with fully-owned innovative medical instrumentation and biotechnology operations), announces today that it has signed a new distribution agreeme…

Third Hospital Joins Multicenter Covid-19 BVA-100® Blood Test Study

NEW YORK, November 19, 2020 — Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that Wake Forest Baptist Health will participate in an ongoing trial to treat patients hosp…
Show more

DAXOR Frequently Asked Questions

  • When was DAXOR founded?

    DAXOR was founded in 1970.

  • Who are DAXOR key executives?

    DAXOR's key executives are Michael R. Feldschuh, Michael Feldschuh and Jonathan Feldschuh.

  • How many employees does DAXOR have?

    DAXOR has 37 employees.

  • What is DAXOR revenue?

    Latest DAXOR annual revenue is $1.4 m.

  • What is DAXOR revenue per employee?

    Latest DAXOR revenue per employee is $39.1 k.

  • Who are DAXOR competitors?

    Competitors of DAXOR include BioMedomics, Dadi and Athelas.

  • Where is DAXOR headquarters?

    DAXOR headquarters is located at 350 5th Ave #4740, New York.

  • Where are DAXOR offices?

    DAXOR has an office in New York.

  • How many offices does DAXOR have?

    DAXOR has 1 office.